Pharmacotherapeutic possibilities of correcting disorders of the primary haemostasis;Farmacotherapeutische mogelijkheden voor correctie van stoornissen in de primaire hemostase

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 7, 1999, Pages 347-351

  Levi, M ^a   Koopman, M M W ^a   Briet E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; DESMOPRESSIN; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SALICYLIC ACID DERIVATIVE;

BLEEDING; BLOOD CLOTTING; DOSE RESPONSE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PERIOPERATIVE PERIOD; REVIEW;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; COAGULATION PROTEIN DISORDERS; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTASIS; HEMOSTATICS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERIOPERATIVE CARE;

EID: 0033550750     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side-effects. Chest 1995;108(4 Suppl):247S-257S.
2. James DN, Fernandes JR, Calder I, Smith M. Low-dose aspirin and intracranial surgery. A survey of the opinions of consultant neuroanaesthetists in the UK. Anaesthesia 1997;52:169-72.
3. Werblin TP, Peiffer RL. Persistent hemorrhage after extracapsular surgery associated with excessive aspirin ingestion. Am J Ophthalmol 1987;104:426.
4. Watson CJ, Deane AM, Doyle PT, Bullock KN. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin. Br J Urol 1990;66:85-7.
5. Zhu JP, Davidsen MB, Meyhoff HH. Aspirin, a silent risk factor in urology. Scand J Urol Nephrol 1995;29:369-74.
6. Billingsley EM, Maloney ME. Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents. A prospective study. Dermatol Surg 1997;23:381-5.
7. Kallis P, Tooze JA, Talbo: S, Cowans D, Bevan DH, Treasure T. Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss - a prospective, randomised, placebo-controlled, double-blind clinical trial in too patients with chronic stable angina. Eur J Cardiothorac Surg 1994;8:404-9.
8. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Improvement in early saphenous vein graft patency alter coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988; 77:1324-32.
9. Bartley GB, Warndahl RA, Surgical bleeding associated with aspirin and nonsteroidal anti-inflammatory agents [letter]. Mayo Clin Proc 1992;67:402-3.
10. Lawrence C, Sakuntabhai A, Tiling-Grosse S. Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients. J Am Acad Dermatol 1994;31:988-92.
11. De Caterina R, Lanza M, Manca G, Strata GB, Maffei S, Salvalore L. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994;84:3363-70.
12. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20.
13. Francis JL. The use of drugs to reduce blood loss during surgery. Hematol Rev 1992;7:85-99.
14. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-21.
15. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103:228-39.
16. Sakariassen KS, Cattaneo M, Berg A van der, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984;64:229-36.
17. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982;59:1272-8.
18. Levi M, Cate JW ten, Dooijewaard G, Sturk A, Brommer EJP, Agnelli G. DDAVP induces systemic release of urokinase-type plasminogen activator. Thromb Haemost 1989;62:686-9.
19. Levi M, Boer JP de, Roem D, Cate JW ten, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992;67:111-6.
20. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet 1977;i:869-72.
21. Castro Cabezas M, Graaf JC de, Kraayenhagen RJ, Freen M, Poortman J, Hart HCh. Desmopressine bij hemofilie A en de ziekte van Von Willebrand. Ned Tijdschr Geneeskd 1991;135:367-71.
22. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990;33:39-45.
23. Rao AK, Ghosh S, Sun L, Yang X, Disa J, Pickens P, et al. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. Thromb Haemost 1995;74:1071-8.
24. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
25. Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG. Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis 1995;25:241-7.
26. Burroughs AK, Matthews K, Quadiri M, Thomas N, Kernoff PBS, Tuddenham EGD, et al. Desmopressin and bleeding time in patients with cirrhosis. Br J Med (Clin Res Ed) 1985;291:1377-81.
27. De Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L. Brunati S, et al. Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopie Club. Hepatology 1993;18:1102-7.
28. Mannucci PM, Vicente V, Vianello L, Cattaneo M, Alberca I, Coccato MP, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148-53.
29. Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg 1993;80:723-4.
30. Flordal PA. Use of desmopressin to prevent bleeding in surgery. Eur J Surg 1998;164:5-11.
31. Kam PC. Use of desmopressin (DDAVP) in controlling aspirin-induced coagulopathy after cardiac surgery. Heart Lung 1994;23: 333-6.
32. Kobrinsky NL, Letts RM, Patel LR, Israels ED, Monson RC, Schwetz N, et al. 1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 1987;107:446-50.
33. Cattaneo M, Harris AS, Strömberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery. Thromb Haemost 1995;74:1064-70.
34. Dantzig JM van, Düren DR, Cate JW ten. Desmopressin and myocardial inflarction. Lancet 1989;i:664-5.
35. Mannucci PM, Lusher JM. Desmopressin and thrombosis [letter]. Lancet 1989;ii:675-6.
36. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa [letter]. Thromb Haemost 1996;75:981-2.
37. Meijer K, Sieders E, Slooff MJH, Meer J van der. Single dose administration of activated recombinant factor VII effective in controlling severe bleeding due to thrombocytopathia. Eur J Int Med 1997;8: C17.
38. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
39. Levi M, Cate JW ten. Antifibrinolytische therapic. Ned Tijdschr Geneeskd 1995;139:613-7.
40. Janssens M, Hartstein G, David JL. Reduction in requirements for allogeneic blood products: pharmacologic methods. Ann Thorac Surg 1996;62:1944-50.
41. Oeveren W van, Eijsman L, Roozendaal KJ, Wildevuur CRH. Platelet preservation by aprotinin during cardiopulmonary bypass [letter]. Lancet 1988;i:644.
42. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85: 1258-67.